COMMUNIQUÉS West-GlobeNewswire

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
27/02/2026
Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge ( [...]
ICPO and UroTeragLATAM signed a strategic agreement to accelerate Theranostics for urological cancer in Latin America
27/02/2026
The partnership strengthens education, innovation, and patient access by combining global expertise with regional leadership in precision oncology. February 27, 2026 – Wiesbaden, Germany and Miami, USA. The [...]
Trading by management and close relations of management
27/02/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
27/02/2026
Pratteln, Switzerland, February 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE® (vamorolone), in the [...]
Herz P1 Smart Band 2026: What It Tracks, How It Works, and What Consumers Should Know Before Buying
27/02/2026
A 2026 Informational Overview of the Herz P1 Smart Band's Subscription-Free Health Monitoring Features, Heart Rate and HRV Tracking, Sleep Quality Analysis, Blood Oxygen and SpO2 Sensors, Stress and Temperature [...]
QuickBurn BHB 2026: What Consumers Should Know About BHB Ketone Supplements Before Buying
27/02/2026
An informational overview of the QuickBurn BHB exogenous ketone supplement — ingredients, BHB salt research, potential side effects, ketosis claims, and what to verify before ordering. Largo, FL, Feb. 26, 2026 (GLOBE [...]
Inventiva to Participate in Four Upcoming March Investor Conferences
26/02/2026
Daix (France), New York (United States), February 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral [...]
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
26/02/2026
WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent [...]
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
26/02/2026
2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4 [...]
BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F
26/02/2026
CHENGDU, China, Feb. 26, 2026 (GLOBE NEWSWIRE) -- BGM Group Ltd. (NASDAQ: BGM) (the “Company” or “BGM”) announced on February 24, 2026, that it has received a notification (the “Notification”) from the Listing [...]
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
26/02/2026
Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. [...]
Extendicare Announces 2025 Fourth Quarter and Full Year Results and Dividend Increase
26/02/2026
MARKHAM, Ontario, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2025. Fourth Quarter 2025 [...]
La Fondation canadienne du rein souligne la nécessité pour les Canadiens d'agir pour leur santé rénale
26/02/2026
Agissez pendant ce Mois de la santé rénale et à l'approche de la Journée mondiale du rein 2026 MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Alors que le Mois de la santé rénale débute, La Fondation canadienne du rein [...]
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
26/02/2026
Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37% Full Year 2025 Net Income of $52.6 million [...]
Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference
26/02/2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
Inventiva participera à quatre conférences investisseurs en mars
26/02/2026
Daix (France), New York ( États-Unis ), le 26 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie [...]
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
26/02/2026
Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended [...]
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
26/02/2026
NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today [...]
Tarsus to Participate in Upcoming Investor Conferences
26/02/2026
IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: TD Cowen 46 th Annual [...]

Pages